SRXN1 and cancer: In anti-cancer trials, maesopsin 4-O-β-D-glucoside (TAT-2) showed antiproliferative effects on acute myeloid leukemia cells and modulated expression of 19 cancer-related genes encoding proteins such as heme oxygenase-1, sulfiredoxin 1 homolog, and breast carcinoma amplified sequence 3 (Pozzesi et al., 2011), and exhibited in vivo anti-cancer effects (Thuy et al., 2016).